Genmab A/S (NASDAQ:GMAB) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in Genmab A/S (NASDAQ:GMAB) by 60.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,447 shares of the company’s stock after selling 21,787 shares during the quarter. SG Americas Securities LLC’s holdings in Genmab A/S were worth $352,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in GMAB. Russell Investments Group Ltd. grew its position in shares of Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares in the last quarter. GAMMA Investing LLC boosted its position in Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after purchasing an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the 1st quarter valued at approximately $43,000. Headlands Technologies LLC boosted its position in Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its position in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $22.98 on Friday. Genmab A/S has a 1 year low of $22.52 and a 1 year high of $32.89. The stock has a fifty day moving average of $25.73 and a two-hundred day moving average of $27.10. The firm has a market capitalization of $15.20 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Equities research analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GMAB. Morgan Stanley restated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Redburn Atlantic began coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. BTIG Research boosted their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.